Effect of gefitinib ('Iressa', ZD1839) on brain metastases in patients with advanced non-small-cell lung cancer.

@article{Hotta2004EffectOG,
  title={Effect of gefitinib ('Iressa', ZD1839) on brain metastases in patients with advanced non-small-cell lung cancer.},
  author={Katsuyuki Hotta and Katsuyuki Kiura and Hiroshi Ueoka and Masahiro Tabata and Keiichi Fujiwara and Toshiyuki Kozuki and Toshiaki Okada and Akiko Hisamoto and Mitsune Tanimoto},
  journal={Lung cancer},
  year={2004},
  volume={46 2},
  pages={255-61}
}
BACKGROUND Gefitinib ('Iressa', ZD1839), an orally active epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (EGFR-TKI), has shown antitumor activity in refractory patients with non-small-cell lung cancer (NSCLC) in clinical trials. We have retrospectively analyzed the efficacy and tolerability of gefitinib in patients with advanced NSCLC treated at Okayama University Hospital. METHODS We reviewed the clinical records of 57 patients with advanced NSCLC who had received 250 mg… CONTINUE READING
78 Extracted Citations
0 Extracted References
Similar Papers

Citing Papers

Publications influenced by this paper.
Showing 1-10 of 78 extracted citations

Similar Papers

Loading similar papers…